News
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...
At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more. ... AstraZeneca’s plenary streak continues: ...
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback